Immunic, Inc. Announces Third Quarter 2025 Financial Results and Updates

Immunic, Inc., a biotechnology firm focused on neurologic and gastrointestinal diseases, released its financial results for Q3 2025. A focal point was the presentation of Vidofludimus Calcium's potential in multiple sclerosis at the ECTRIMS Congress. Phase 2 CALLIPER data indicated statistically significant improvements in disability for progressive multiple sclerosis patients. Long-term data from the Phase 2 EMPhASIS trial also showed favorable safety outcomes.

Financially, R&D expenses slightly decreased to $20.0 million for Q3 2025 compared to the previous year. General and administrative expenses rose to $6.0 million, attributed mainly to increased personnel costs. Net loss for Q3 was $25.6 million, a slight increase from the previous year.

Despite strong intellectual property enhancements, Immunic noted that it requires additional capital, as cash reserves stood at $35.1 million. The company anticipates reporting Phase 3 ENSURE trial top-line data in 2026.